Ventura Offshore Holding Ltd. (OSL:VTURA)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Mar 31, 2025	Dec 31, 2024
Operating Revenue	304.73	228.19
Other Revenue	81.55	62.12
Revenue	386.28	290.31
Gross Profit	386.28	290.31
Selling, General & Admin	140.16	103.57
Other Operating Expenses	81.72	62.31
Operating Expenses	255.4	191.55
Operating Income	130.89	98.76
Interest Expense	-20.51	-15.51
Interest & Investment Income	1.59	1.52
EBT Excluding Unusual Items	111.96	84.76
Merger & Restructuring Charges	-4.56	-4.56
Pretax Income	107.4	80.2
Income Tax Expense	14.92	11
Net Income	92.48	69.2
Net Income to Common	92.48	69.2
Shares Outstanding (Basic)	106	76
Shares Outstanding (Diluted)	106	78
EPS (Basic)	0.87	0.91
EPS (Diluted)	0.87	0.89
Free Cash Flow	-120.2	-102.85
Free Cash Flow Per Share	-1.14	-1.32
Gross Margin	100.00%	100.00%
Operating Margin	33.88%	34.02%
Profit Margin	23.94%	23.84%
Free Cash Flow Margin	-31.12%	-35.43%
EBITDA	-	124.43
EBITDA Margin	-	42.86%
D&A For EBITDA	-	25.68
EBIT	130.89	98.76
EBIT Margin	33.88%	34.02%
Effective Tax Rate	13.89%	13.72%
Revenue as Reported	386.28	290.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.